Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Abstract: The present disclosure relates to inhibitors of NLRP3 of Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof. The compound of formula (I) can be useful for the treatment of a disease or condition for which a cGAS inhibitor is indicated. In some embodiments, the compound or its pharmaceutically acceptable salt, solvate, ester or prodrug thereof can be used for the treatment of an autoinflammation or an autoimmune disease such as systemic lupus erythematosus (SLE), Aicardi-Goutieres syndrome (AGS), nonalcoholic steatohepatitis (NASH), Age-dependent macular degeneration, Myocardial infarction, Acute pancreatitis, Ischemic stroke, Sporadic aortic aneurysm and dissection, Chronic lung disease, Inflammatory bowel disease, Parkinson's disease, Traumatic brain injury or Amyotrophic lateral sclerosis (ALS).

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.